Sun Piaoyang Net Worth

Sun Piaoyang has an estimated net worth of $10.9 billion, according to Forbes Real-Time Billionaires, Sun Piaoyang profile (figures as of October 20, 2026). That is up from $8.4 billion in 2019.

Sun Piaoyang is a Chinese pharmaceutical executive and the chairman of Jiangsu Hengrui Pharmaceuticals, one of China's largest makers of anti-infection and cancer drugs. He was born in 1958. He holds a bachelor's degree from China Pharmaceutical University and a doctorate from Nanjing University.

Sun is part of one of China's most prominent pharmaceutical families. His wife, Zhong Huijuan, is also a billionaire. She is chairman and CEO of Hansoh Pharmaceutical Group, a drug maker that listed on the Hong Kong Stock Exchange in 2019. Their daughter, Sun Yuan, is Hansoh's executive director.

Together the couple control two of China's leading drug companies, a rare pairing in the global pharmaceutical industry. Their businesses benefit from China's growing spending on health care and its push to develop new medicines at home rather than rely on imports.

How Sun Piaoyang made his money

Sun took over Hengrui in 1990, when it was a state-led company and he was 32 years old. He steered it away from its old model and built it into a major drug developer focused on medicines for infections and tumors. He took Hengrui public in Shanghai in 2000, which turned his stake into a large fortune as the business grew.

In 2025 he led the company to a second listing in Hong Kong, raising $1.3 billion. That move gave Hengrui more access to international investors as it pushes its newer drugs abroad. His stake in Hengrui is the main source of his wealth, and its value rises and falls with the company's share price.

Hengrui has spent heavily on research to move beyond copies of older drugs and develop its own new treatments, especially for cancer. That shift has made it one of the most closely watched drug makers in Asia.

How Forbes has valued Sun Piaoyang

Forbes valued Sun at $8.4 billion in 2019. Hengrui shares then surged, lifting him to $11.8 billion in 2020 and $18.9 billion in 2021, his peak. His figure fell to $17.1 billion in 2022 and then dropped sharply to $9.7 billion in 2023.

It slipped again to $8.8 billion in 2024 before recovering to $9.5 billion in 2025. On the 2026 World's Billionaires List Forbes put him at $12.4 billion. As of October 20, 2026, the Forbes real-time billionaires tracker showed $10.9 billion. His estimates have closely tracked investor mood toward Chinese drug stocks.